Back to the archive
18/04/2016| Angelini confirms commitment in Infection Control and Infectious Diseases Area

Rome, April 18, 2016 – Angelini is an international group leader in the Rx and OTC pharmaceutical sector  focused on Pain & Inflammation Disorders, Infection Control & Infectious Diseases, and Nervous System Diseases & Disorders.

Recently in the Infection Control & Infectious Diseases therapy area, Angelini entered into a license agreement with Allergan to commercialize dalbavancin, a second generation, semi-synthetic lipoglycopeptide, in several countries, which include Italy, Spain, Poland, Portugal and many Eastern European countries, including Russia and Turkey.

Dalbavancin  is approved for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).

Starting with the experience of the development of prulifloxacin, Angelini R&D gradually became more involved in Infection Control & Infectious Diseases, an area where pharmacological research has become a priority focusing on emerging antibiotic resistance. Angelini has an outstanding R&D pipeline in anti-infectives, including research on New Chemical Entities and the lifecycle management of the existing products.

Data from Angelini research projects elucidate the mechanism of action of original compounds that act as dual topoisomerase II or as b-lactamase inhibitors, and further characterize their enzymatic and microbiological properties. They also allowed researchers at Angelini to identify novel inhibitors.

Moreover, clinical studies with prulifloxacin permitted to establish the correct dose regimen for renal impaired patients.

These data from Angelini were presented at the 26th European Congress in Clinical Microbiology and infectious Diseases (ECCMID), 09 – 12 April 2016 / Nertherlands, Amsterdam:

Poster Session: “Discovery of more new antibacterial drugs”

  • Novel class of dual topoisomerase II inhibitors: study on mode of action
  • Identification of novel IMP-1, VIM-1 and NDM-1 metallo-beta-lactamase inhibitors
  • Advanced use of high-throughput screening tools for the identification of novel OXA-48 beta-lactamase inhibitors for infection treatment

ePosters Session: “Pharmacokinetics/Pharmacodynamics of antibacterial drugs and therapeutic drug monitoring”

  • An in depth investigation on prulifloxacin dosage adjustment in mild, moderate and severe renal impairment

Angelini was the only Italian Pharmaceutical company to be present at the ECCMID congress where they presented their innovative pipeline data and had a major presence in the exhibition hall.

 

ABOUT DALBAVANCIN

Dalbavancin for injection is a second generation, semi-synthetic lipoglycopeptide, which consists of a lipophilic side-chain added to an enhanced glycopeptide backbone. Dalbavancin is the first and only IV antibiotic approved for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), with  both a two-dose regimen of 1000 mg followed one week later by 500 mg, each administered over 30 minutes, and a single dose regimen of 1500 mg also administered over 30 minutes. Dalbavancin demonstrates bactericidal activity in vitro against a range of Gram-positive bacteria, such as Staphylococcus aureus (including methicillin-resistant, also known as MRSA, strains) and Staphylococcus pyogenes, as well as certain other streptococcal species.

Angelini has licensed dalbavancin from Durata Therapeutics, now Allergan plc, to commercialize the product in several territories, including Italy, Spain, Poland, Portugal, many Eastern European countries, Russia and Turkey.

 

Download the press release

Back to the archive